Bicara Therapeutics growth playbook

Put the real FORTIFI inquiries contact (or a trial-navigation service) in the menu block on both language versions, today. Then add a short, IRB-approved "Can I take part?" form that routes to the nearest of the 49 listed US centers, a clinician referral path in the "For Clinicians" section, and click and form tracking so the trial team can see which channel produces pre-screened referrals.

Recruitment sites are judged by the contacts they produce, and most visitors arrive on phones. Removing a dead end and adding a routed form is the cheapest enrollment gain available, and the marketing operations hire is chartered to keep deployed content approved and current across channels.

[ ] Menu panel phone = real FORTIFI line (English and Spanish)
[ ] Menu panel email = FORTIFI inquiries address
[ ] No other template text on either page
[ ] Spanish page title and description in Spanish
[ ] Call and email clicks tracked
[ ] Pre-screen form submitted to IRB
[ ] Clinician referral contact under For Clinicians

• IRB approval needed for new recruitment wording

  Fix the contact details first (no new claims) and submit the form wording in parallel.

• Inquiries overwhelm sites

  Use a central navigator to pre-screen before sites are contacted.

• Trial websitefortificlinicaltrial.com, the FORTIFI-HN01 recruitment site linked from bicara.com/patients, checked twice on October 22, 2026: the "Get in touch" block in the menu panel (the menu shown on tablets and phones) reads "555-555-5555" and "[email removed]", which are website-template placeholders. The page lists 49 US study centers in 25 states, says "For US audiences only", has no patient or clinician referral form, and does not mention the FORTIFI-FLEX study.Source
• ClinicalTrials.govNCT06788990 (FORTIFI-HN01) is RECRUITING, estimated enrollment 650, record updated October 2, 2026, with 231 listed sites (55 in the US, 20 in Brazil, 18 in Italy, 15 each in Germany and the UK, sites in 28 countries). Central contact: Medical Affairs, 1-617-468-4219, [email protected]. FORTIFI-FLEX (NCT07807163, estimated 160) is also RECRUITING, record updated October 13, 2026.Source
• Trial websiteThe Spanish version (fortificlinicaltrial.com/es-mx) translates the page but keeps the English title "HNSCC Clinical Trial Now Enrolling Near You" and English meta description, and its menu panel shows the same placeholder phone and email.Source
• Company updateQ1 2026 results (May 11, 2026): Bicara expects FORTIFI-HN01 to be "substantially enrolled by the end of the year" to enable an interim analysis in mid-2027 to support potential accelerated approval; cash, cash equivalents and marketable securities of $539.8 million fund operations "into the first half of 2029"; a Chief Commercial Officer was appointed to "lead the commercial organization in preparation for launch readiness"; the company is "rapidly evolving toward becoming a commercial-stage company".Source
• HiringDirector, Marketing Operations (posted August 21, 2026): will "Build the marketing operations function from the ground up", chair the Promotional Medical Review Committee (PMRC), set up MLR workflows and KPIs, own the commercial congress calendar, and "Ensure approved content is appropriately deployed, version-controlled, tracked, and retired across channels", including "email marketing, digital advertising, HCP websites, virtual programs".Source

Write a Spanish title and description, add hreflang links between the English and Spanish pages, and include the Spanish page in a sitemap. Share the Spanish link with the US centers that serve Spanish-speaking patients.

Matching the search snippet to the reader's language raises clicks, and the translated page already exists.

• Translation not approved

  Use the already-approved Spanish body text for the snippet.

• Trial websiteThe Spanish version (fortificlinicaltrial.com/es-mx) translates the page but keeps the English title "HNSCC Clinical Trial Now Enrolling Near You" and English meta description, and its menu panel shows the same placeholder phone and email.Source
• Trial websitefortificlinicaltrial.com, the FORTIFI-HN01 recruitment site linked from bicara.com/patients, checked twice on October 22, 2026: the "Get in touch" block in the menu panel (the menu shown on tablets and phones) reads "555-555-5555" and "[email removed]", which are website-template placeholders. The page lists 49 US study centers in 25 states, says "For US audiences only", has no patient or clinician referral form, and does not mention the FORTIFI-FLEX study.Source
• ClinicalTrials.govNCT06788990 (FORTIFI-HN01) is RECRUITING, estimated enrollment 650, record updated October 2, 2026, with 231 listed sites (55 in the US, 20 in Brazil, 18 in Italy, 15 each in Germany and the UK, sites in 28 countries). Central contact: Medical Affairs, 1-617-468-4219, [email protected]. FORTIFI-FLEX (NCT07807163, estimated 160) is also RECRUITING, record updated October 13, 2026.Source

Render page content into the HTML on the server (server-side or pre-rendered pages), keep the Vue interactions on top, and give each page its own meta description (the Expanded Access page reuses the homepage's). Test with a no-JavaScript fetch and a link-preview check.

HCPs and patients increasingly ask AI tools about trials and mechanisms, and the HCP marketing role will run digital and omnichannel programs that point to these pages.

• Theme rebuild cost

  Pre-render as a first step; full rebuild later if needed.

• Your websitebicara.com is a WordPress site whose page text is delivered inside a script variable and drawn by JavaScript: a plain fetch of /patients/ or /science/ returns only the menu words as page text. The Expanded Access Policy page reuses the homepage meta description. Seven job pages from January to March 2025 (/position/...) are still live and listed in the sitemap, while current roles are on the Ashby board.Source
• HiringDirector, HCP Marketing (Boston, posted October 16, 2026): leads HCP marketing strategy for ficerafusp alfa "as Bicara prepares for potential US FDA approval"; develops "the HCP launch plan across key channels, including personal promotion, digital/media marketing, peer-to-peer promotions, and congress"; oversees "omnichannel digital and media strategy"; part of "the launch readiness team".Source
• HiringDirector, Marketing Operations (posted August 21, 2026): will "Build the marketing operations function from the ground up", chair the Promotional Medical Review Committee (PMRC), set up MLR workflows and KPIs, own the commercial congress calendar, and "Ensure approved content is appropriately deployed, version-controlled, tracked, and retired across channels", including "email marketing, digital advertising, HCP websites, virtual programs".Source
• Your websitePatients page: a patient quote, downloadable Patient Resource and Caregiver guides, descriptions of FORTIFI-HN01, FORTIFI-FLEX and the Phase 1b study, a Patient Education Center on HNSCC (an estimated 80% of R/M HNSCC cases are HPV-negative) and links to ClinicalTrials.gov and the trial site. The Expanded Access page says Bicara "does not currently offer" expanded access and gives a contact address for healthcare providers.Source

Serve the hero and page images in WebP or AVIF at phone sizes, preload the hero, and defer render-blocking requests. Recheck PageSpeed and the field data after a month.

Investors, candidates and HCPs often first see the site on phones from links in emails and posts.

• Visual quality loss

  Compare before and after on retina screens.

• Google PageSpeedHomepage, mobile lab test: performance 48 (desktop 91), Largest Contentful Paint 10.9 s on the hero image, 2.1 MB page with 1.2 MB of images; estimated savings of 1.1 MB from better image delivery and 1.75 s from render-blocking requests. Real Chrome visitors fail Core Web Vitals on LCP: 3.9 s at the 75th percentile (target 2.5 s); INP 98 ms and CLS 0 pass.Source

Redirect the old position pages to the careers page, drop them from the sitemap, and link the careers page to the live Ashby board.

A clean careers path helps hiring for the launch team and removes a source of confusion that scammers exploit.

• Lost links

  Redirect rather than delete.

• Your websitebicara.com is a WordPress site whose page text is delivered inside a script variable and drawn by JavaScript: a plain fetch of /patients/ or /science/ returns only the menu words as page text. The Expanded Access Policy page reuses the homepage meta description. Seven job pages from January to March 2025 (/position/...) are still live and listed in the sitemap, while current roles are on the Ashby board.Source
• Your websiteCareers page: values ("Patient Driven, Highly Adaptive, Openly Candid") and a warning that "All formal communication regarding job opportunities at Bicara will come exclusively from an official @bicara.com email address"; the About page announces leadership transitions effective January 1, 2027.Source

Add a short FLEX section with eligibility basics, locations and the ClinicalTrials.gov link, and a "which study might fit me" note that routes to the same inquiry form.

One trusted recruitment address serves more patients and gives referring doctors one link to remember.

• Confusing two studies

  Keep each section short with a clear contact.

• Trial websitefortificlinicaltrial.com, the FORTIFI-HN01 recruitment site linked from bicara.com/patients, checked twice on October 22, 2026: the "Get in touch" block in the menu panel (the menu shown on tablets and phones) reads "555-555-5555" and "[email removed]", which are website-template placeholders. The page lists 49 US study centers in 25 states, says "For US audiences only", has no patient or clinician referral form, and does not mention the FORTIFI-FLEX study.Source
• ClinicalTrials.govNCT06788990 (FORTIFI-HN01) is RECRUITING, estimated enrollment 650, record updated October 2, 2026, with 231 listed sites (55 in the US, 20 in Brazil, 18 in Italy, 15 each in Germany and the UK, sites in 28 countries). Central contact: Medical Affairs, 1-617-468-4219, [email protected]. FORTIFI-FLEX (NCT07807163, estimated 160) is also RECRUITING, record updated October 13, 2026.Source
• Your websitePatients page: a patient quote, downloadable Patient Resource and Caregiver guides, descriptions of FORTIFI-HN01, FORTIFI-FLEX and the Phase 1b study, a Patient Education Center on HNSCC (an estimated 80% of R/M HNSCC cases are HPV-negative) and links to ClinicalTrials.gov and the trial site. The Expanded Access page says Bicara "does not currently offer" expanded access and gives a contact address for healthcare providers.Source

Map community oncology and ENT practices within driving distance of each center, give MSLs a compliant protocol summary and referral contact to share on request, and track referrals and screen outcomes by practice.

Referrals from the doctors who see patients first are the steadiest source of enrollment.

• Promotional concerns

  Medical affairs owns it; no product claims.

• HiringSenior Medical Science Liaison - West (CA, WA), posted August 17, 2026: "fair and balanced education on investigational products", relationships with investigators and institutions, the investigator-initiated research program, and "responses to unsolicited requests for medical information"; plus a Senior Clinical Trial Manager (posted September 17, 2026).Source
• Trial websitefortificlinicaltrial.com, the FORTIFI-HN01 recruitment site linked from bicara.com/patients, checked twice on October 22, 2026: the "Get in touch" block in the menu panel (the menu shown on tablets and phones) reads "555-555-5555" and "[email removed]", which are website-template placeholders. The page lists 49 US study centers in 25 states, says "For US audiences only", has no patient or clinician referral form, and does not mention the FORTIFI-FLEX study.Source
• ClinicalTrials.govNCT06788990 (FORTIFI-HN01) is RECRUITING, estimated enrollment 650, record updated October 2, 2026, with 231 listed sites (55 in the US, 20 in Brazil, 18 in Italy, 15 each in Germany and the UK, sites in 28 countries). Central contact: Medical Affairs, 1-617-468-4219, [email protected]. FORTIFI-FLEX (NCT07807163, estimated 160) is also RECRUITING, record updated October 13, 2026.Source
• Company updateQ1 2026 results (May 11, 2026): Bicara expects FORTIFI-HN01 to be "substantially enrolled by the end of the year" to enable an interim analysis in mid-2027 to support potential accelerated approval; cash, cash equivalents and marketable securities of $539.8 million fund operations "into the first half of 2029"; a Chief Commercial Officer was appointed to "lead the commercial organization in preparation for launch readiness"; the company is "rapidly evolving toward becoming a commercial-stage company".Source

Build a publication library with filters (congress, year, study, tumor type), one-line plain summaries, the PDF and the citation, and a plain-language summary where allowed. Keep it under medical affairs, with no promotional framing.

It makes the evidence easy to find for HCPs and journalists and becomes the home for each new congress release.

• Promotional appearance

  Medical review owns the library.

• Your websiteSitemap (80 URLs): 27 presentations and publications (ASCO 2023 to ASCO 2026, ESMO, SITC, a 2026 Journal of Clinical Oncology paper), each a separate page with a long title; 31 team pages; no HCP-specific section, no disease-awareness hub beyond the Patients page, and no news posts on the site (press releases live on ir.bicara.com).Source
• HiringAssociate Director, Global Scientific Communications (posted July 6, 2026, still open): runs the global publication plan (manuscripts, abstracts, posters and "digital publication extenders"), pulls the Scientific Communication Platform into all deliverables, and builds slide decks, FAQs and "interactive educational tools" for field medical teams, under GPP2022 and ICMJE rules.Source

Build an unbranded disease hub for oncologists: HPV status testing, PD-L1 scoring, patterns of recurrence and current guidelines, with downloadable tools. Use it to build an opted-in HCP audience and test messages.

It gives the launch team a compliant audience, data on what HCPs care about, and a channel ready for launch.

• Seen as pre-approval promotion

  Strictly unbranded content with no product mention, reviewed by PMRC.

• HiringDirector, HCP Marketing (Boston, posted October 16, 2026): leads HCP marketing strategy for ficerafusp alfa "as Bicara prepares for potential US FDA approval"; develops "the HCP launch plan across key channels, including personal promotion, digital/media marketing, peer-to-peer promotions, and congress"; oversees "omnichannel digital and media strategy"; part of "the launch readiness team".Source
• HiringSenior Director, Brand Lead - US (posted September 25, 2026): the "day-to-day brand owner" who builds the integrated brand plan "across HCP, patient, digital, field, and other customer channels", leads message testing, segmentation and customer journey research, "Day 0 planning", and engagement for "medical oncologists, academic and community oncology practices".Source
• Your websitePatients page: a patient quote, downloadable Patient Resource and Caregiver guides, descriptions of FORTIFI-HN01, FORTIFI-FLEX and the Phase 1b study, a Patient Education Center on HNSCC (an estimated 80% of R/M HNSCC cases are HPV-negative) and links to ClinicalTrials.gov and the trial site. The Expanded Access page says Bicara "does not currently offer" expanded access and gives a contact address for healthcare providers.Source

Build a register of every public asset (bicara.com, the trial site, PDFs, congress pages), with owner, approval number, review date and expiry. Add a quarterly live-page check against approved versions.

Launch multiplies assets; a register built now prevents off-label or outdated content going live later.

• Extra process slows teams

  Keep the register light.

• HiringDirector, Marketing Operations (posted August 21, 2026): will "Build the marketing operations function from the ground up", chair the Promotional Medical Review Committee (PMRC), set up MLR workflows and KPIs, own the commercial congress calendar, and "Ensure approved content is appropriately deployed, version-controlled, tracked, and retired across channels", including "email marketing, digital advertising, HCP websites, virtual programs".Source
• Trial websitefortificlinicaltrial.com, the FORTIFI-HN01 recruitment site linked from bicara.com/patients, checked twice on October 22, 2026: the "Get in touch" block in the menu panel (the menu shown on tablets and phones) reads "555-555-5555" and "[email removed]", which are website-template placeholders. The page lists 49 US study centers in 25 states, says "For US audiences only", has no patient or clinician referral form, and does not mention the FORTIFI-FLEX study.Source
• Your websitePatients page: a patient quote, downloadable Patient Resource and Caregiver guides, descriptions of FORTIFI-HN01, FORTIFI-FLEX and the Phase 1b study, a Patient Education Center on HNSCC (an estimated 80% of R/M HNSCC cases are HPV-negative) and links to ClinicalTrials.gov and the trial site. The Expanded Access page says Bicara "does not currently offer" expanded access and gives a contact address for healthcare providers.Source

Build simple country pages in local languages for the largest countries (Brazil, Italy, Germany, the UK, France, Spain), each approved by local ethics committees, with site lists and contacts.

Most sites are outside the US, and local-language pages help referring doctors and families act.

• Country rules differ

  Use local CRO partners for approvals.

• ClinicalTrials.govNCT06788990 (FORTIFI-HN01) is RECRUITING, estimated enrollment 650, record updated October 2, 2026, with 231 listed sites (55 in the US, 20 in Brazil, 18 in Italy, 15 each in Germany and the UK, sites in 28 countries). Central contact: Medical Affairs, 1-617-468-4219, [email protected]. FORTIFI-FLEX (NCT07807163, estimated 160) is also RECRUITING, record updated October 13, 2026.Source
• Trial websitefortificlinicaltrial.com, the FORTIFI-HN01 recruitment site linked from bicara.com/patients, checked twice on October 22, 2026: the "Get in touch" block in the menu panel (the menu shown on tablets and phones) reads "555-555-5555" and "[email removed]", which are website-template placeholders. The page lists 49 US study centers in 25 states, says "For US audiences only", has no patient or clinician referral form, and does not mention the FORTIFI-FLEX study.Source
• Company updateQ1 2026 results (May 11, 2026): Bicara expects FORTIFI-HN01 to be "substantially enrolled by the end of the year" to enable an interim analysis in mid-2027 to support potential accelerated approval; cash, cash equivalents and marketable securities of $539.8 million fund operations "into the first half of 2029"; a Chief Commercial Officer was appointed to "lead the commercial organization in preparation for launch readiness"; the company is "rapidly evolving toward becoming a commercial-stage company".Source

Offer grants and joint webinars on living with recurrent disease and finding trials, with a neutral trial-finder resource the groups control.

Advocacy partners are trusted sources, and the help reaches caregivers who search for options.

• Independence concerns

  Groups control content.

• Your websitePatients page: a patient quote, downloadable Patient Resource and Caregiver guides, descriptions of FORTIFI-HN01, FORTIFI-FLEX and the Phase 1b study, a Patient Education Center on HNSCC (an estimated 80% of R/M HNSCC cases are HPV-negative) and links to ClinicalTrials.gov and the trial site. The Expanded Access page says Bicara "does not currently offer" expanded access and gives a contact address for healthcare providers.Source
• Trial websitefortificlinicaltrial.com, the FORTIFI-HN01 recruitment site linked from bicara.com/patients, checked twice on October 22, 2026: the "Get in touch" block in the menu panel (the menu shown on tablets and phones) reads "555-555-5555" and "[email removed]", which are website-template placeholders. The page lists 49 US study centers in 25 states, says "For US audiences only", has no patient or clinician referral form, and does not mention the FORTIFI-FLEX study.Source

Write plain-language summaries for the key publications, reviewed by patient advisers, and link them from the Patients page.

Caregivers research deeply after recurrence; clear summaries build trust.

• Implied claims

  Follow GPP2022 and MLR.

• HiringAssociate Director, Global Scientific Communications (posted July 6, 2026, still open): runs the global publication plan (manuscripts, abstracts, posters and "digital publication extenders"), pulls the Scientific Communication Platform into all deliverables, and builds slide decks, FAQs and "interactive educational tools" for field medical teams, under GPP2022 and ICMJE rules.Source
• Your websiteSitemap (80 URLs): 27 presentations and publications (ASCO 2023 to ASCO 2026, ESMO, SITC, a 2026 Journal of Clinical Oncology paper), each a separate page with a long title; 31 team pages; no HCP-specific section, no disease-awareness hub beyond the Patients page, and no news posts on the site (press releases live on ir.bicara.com).Source
• Your websitePatients page: a patient quote, downloadable Patient Resource and Caregiver guides, descriptions of FORTIFI-HN01, FORTIFI-FLEX and the Phase 1b study, a Patient Education Center on HNSCC (an estimated 80% of R/M HNSCC cases are HPV-negative) and links to ClinicalTrials.gov and the trial site. The Expanded Access page says Bicara "does not currently offer" expanded access and gives a contact address for healthcare providers.Source

Run journey interviews with 30 community and academic oncologists on HPV testing, first-line choices and referral, and segment by site of care.

Launch messaging built on real journeys avoids an expensive repositioning later.

• Small samples

  Mix interviews and a survey.

• HiringSenior Director, Brand Lead - US (posted September 25, 2026): the "day-to-day brand owner" who builds the integrated brand plan "across HCP, patient, digital, field, and other customer channels", leads message testing, segmentation and customer journey research, "Day 0 planning", and engagement for "medical oncologists, academic and community oncology practices".Source
• Competitor researchOther first-line R/M HNSCC Phase 3 programs on ClinicalTrials.gov: Merus's LiGeR-HN1 (petosemtamab plus pembrolizumab vs pembrolizumab, NCT06525220, active, not recruiting) and Janssen's OrigAMI-5 (amivantamab added to carboplatin and pembrolizumab, NCT07276399, recruiting). Both are EGFR-directed approaches in the same setting.See the research Source
• HiringDirector, HCP Marketing (Boston, posted October 16, 2026): leads HCP marketing strategy for ficerafusp alfa "as Bicara prepares for potential US FDA approval"; develops "the HCP launch plan across key channels, including personal promotion, digital/media marketing, peer-to-peer promotions, and congress"; oversees "omnichannel digital and media strategy"; part of "the launch readiness team".Source

For each major congress, publish a medical-affairs page with posters, sessions and a request-for-information form, and follow up with interested HCPs.

Congresses are where specialists form views; a follow-up path captures that interest.

• Promotional drift

  Medical affairs owns the page.

• HiringDirector, HCP Marketing (Boston, posted October 16, 2026): leads HCP marketing strategy for ficerafusp alfa "as Bicara prepares for potential US FDA approval"; develops "the HCP launch plan across key channels, including personal promotion, digital/media marketing, peer-to-peer promotions, and congress"; oversees "omnichannel digital and media strategy"; part of "the launch readiness team".Source
• HiringDirector, Marketing Operations (posted August 21, 2026): will "Build the marketing operations function from the ground up", chair the Promotional Medical Review Committee (PMRC), set up MLR workflows and KPIs, own the commercial congress calendar, and "Ensure approved content is appropriately deployed, version-controlled, tracked, and retired across channels", including "email marketing, digital advertising, HCP websites, virtual programs".Source
• Your websiteSitemap (80 URLs): 27 presentations and publications (ASCO 2023 to ASCO 2026, ESMO, SITC, a 2026 Journal of Clinical Oncology paper), each a separate page with a long title; 31 team pages; no HCP-specific section, no disease-awareness hub beyond the Patients page, and no news posts on the site (press releases live on ir.bicara.com).Source

Add a news feed from the IR releases to the homepage and News page, and an email signup for updates.

Visible momentum helps recruiting, partnerships and investor interest.

• Disclosure timing

  Feed only after IR publication.

• Your websiteSitemap (80 URLs): 27 presentations and publications (ASCO 2023 to ASCO 2026, ESMO, SITC, a 2026 Journal of Clinical Oncology paper), each a separate page with a long title; 31 team pages; no HCP-specific section, no disease-awareness hub beyond the Patients page, and no news posts on the site (press releases live on ir.bicara.com).Source
• Company updateQ1 2026 results (May 11, 2026): Bicara expects FORTIFI-HN01 to be "substantially enrolled by the end of the year" to enable an interim analysis in mid-2027 to support potential accelerated approval; cash, cash equivalents and marketable securities of $539.8 million fund operations "into the first half of 2029"; a Chief Commercial Officer was appointed to "lead the commercial organization in preparation for launch readiness"; the company is "rapidly evolving toward becoming a commercial-stage company".Source
• Your websiteCareers page: values ("Patient Driven, Highly Adaptive, Openly Candid") and a warning that "All formal communication regarding job opportunities at Bicara will come exclusively from an official @bicara.com email address"; the About page announces leadership transitions effective January 1, 2027.Source

Select and implement CRM, consent management, content approval and analytics as one stack, with HCP consent captured from the disease hub and congress pages.

A ready stack means launch-day campaigns run on real audiences.

• Built before needs are clear

  Phase it.

• Company updateQ1 2026 results (May 11, 2026): Bicara expects FORTIFI-HN01 to be "substantially enrolled by the end of the year" to enable an interim analysis in mid-2027 to support potential accelerated approval; cash, cash equivalents and marketable securities of $539.8 million fund operations "into the first half of 2029"; a Chief Commercial Officer was appointed to "lead the commercial organization in preparation for launch readiness"; the company is "rapidly evolving toward becoming a commercial-stage company".Source
• HiringDirector, Marketing Operations (posted August 21, 2026): will "Build the marketing operations function from the ground up", chair the Promotional Medical Review Committee (PMRC), set up MLR workflows and KPIs, own the commercial congress calendar, and "Ensure approved content is appropriately deployed, version-controlled, tracked, and retired across channels", including "email marketing, digital advertising, HCP websites, virtual programs".Source
• HiringDirector, HCP Marketing (Boston, posted October 16, 2026): leads HCP marketing strategy for ficerafusp alfa "as Bicara prepares for potential US FDA approval"; develops "the HCP launch plan across key channels, including personal promotion, digital/media marketing, peer-to-peer promotions, and congress"; oversees "omnichannel digital and media strategy"; part of "the launch readiness team".Source
• HiringSenior Director, Brand Lead - US (posted September 25, 2026): the "day-to-day brand owner" who builds the integrated brand plan "across HCP, patient, digital, field, and other customer channels", leads message testing, segmentation and customer journey research, "Day 0 planning", and engagement for "medical oncologists, academic and community oncology practices".Source

Run research with caregivers and trial site nurses on practical barriers (travel, nutrition, swallowing, cost) and design hub services from it.

Services built from lived barriers support access at launch.

• Pre-approval limits

  Research only until approval.

• HiringSenior Director, Brand Lead - US (posted September 25, 2026): the "day-to-day brand owner" who builds the integrated brand plan "across HCP, patient, digital, field, and other customer channels", leads message testing, segmentation and customer journey research, "Day 0 planning", and engagement for "medical oncologists, academic and community oncology practices".Source
• Your websitePatients page: a patient quote, downloadable Patient Resource and Caregiver guides, descriptions of FORTIFI-HN01, FORTIFI-FLEX and the Phase 1b study, a Patient Education Center on HNSCC (an estimated 80% of R/M HNSCC cases are HPV-negative) and links to ClinicalTrials.gov and the trial site. The Expanded Access page says Bicara "does not currently offer" expanded access and gives a contact address for healthcare providers.Source
• Trial websitefortificlinicaltrial.com, the FORTIFI-HN01 recruitment site linked from bicara.com/patients, checked twice on October 22, 2026: the "Get in touch" block in the menu panel (the menu shown on tablets and phones) reads "555-555-5555" and "[email removed]", which are website-template placeholders. The page lists 49 US study centers in 25 states, says "For US audiences only", has no patient or clinician referral form, and does not mention the FORTIFI-FLEX study.Source

Build a mechanism-focused scientific exchange resource (animations, slides, FAQs) for MSLs that is consistent across tumors and updated with each data release.

Consistent science builds credibility across indications.

• Overreach

  Strict scientific exchange rules.

• HiringAssociate Director, Global Scientific Communications (posted July 6, 2026, still open): runs the global publication plan (manuscripts, abstracts, posters and "digital publication extenders"), pulls the Scientific Communication Platform into all deliverables, and builds slide decks, FAQs and "interactive educational tools" for field medical teams, under GPP2022 and ICMJE rules.Source
• Your websiteSitemap (80 URLs): 27 presentations and publications (ASCO 2023 to ASCO 2026, ESMO, SITC, a 2026 Journal of Clinical Oncology paper), each a separate page with a long title; 31 team pages; no HCP-specific section, no disease-awareness hub beyond the Patients page, and no news posts on the site (press releases live on ir.bicara.com).Source
• HiringSenior Medical Science Liaison - West (CA, WA), posted August 17, 2026: "fair and balanced education on investigational products", relationships with investigators and institutions, the investigator-initiated research program, and "responses to unsolicited requests for medical information"; plus a Senior Clinical Trial Manager (posted September 17, 2026).Source

Audit every listing of FORTIFI-HN01 and FLEX (registry, trial-finder sites, center pages) and align contacts and links; add structured data to the trial page.

Consistency helps patients and referring doctors reach the right team.

• Third parties slow

  Prioritize the biggest finders.

• Trial websitefortificlinicaltrial.com, the FORTIFI-HN01 recruitment site linked from bicara.com/patients, checked twice on October 22, 2026: the "Get in touch" block in the menu panel (the menu shown on tablets and phones) reads "555-555-5555" and "[email removed]", which are website-template placeholders. The page lists 49 US study centers in 25 states, says "For US audiences only", has no patient or clinician referral form, and does not mention the FORTIFI-FLEX study.Source
• ClinicalTrials.govNCT06788990 (FORTIFI-HN01) is RECRUITING, estimated enrollment 650, record updated October 2, 2026, with 231 listed sites (55 in the US, 20 in Brazil, 18 in Italy, 15 each in Germany and the UK, sites in 28 countries). Central contact: Medical Affairs, 1-617-468-4219, [email protected]. FORTIFI-FLEX (NCT07807163, estimated 160) is also RECRUITING, record updated October 13, 2026.Source
• Your websitebicara.com is a WordPress site whose page text is delivered inside a script variable and drawn by JavaScript: a plain fetch of /patients/ or /science/ returns only the menu words as page text. The Expanded Access Policy page reuses the homepage meta description. Seven job pages from January to March 2025 (/position/...) are still live and listed in the sitemap, while current roles are on the Ashby board.Source

Add a commercial careers page: launch team structure, leaders' backgrounds and what the first hires build, linking to Ashby roles.

Experienced launch talent chooses companies with a clear plan.

• Forward-looking statements

  Legal review.

• Your websiteCareers page: values ("Patient Driven, Highly Adaptive, Openly Candid") and a warning that "All formal communication regarding job opportunities at Bicara will come exclusively from an official @bicara.com email address"; the About page announces leadership transitions effective January 1, 2027.Source
• Company updateQ1 2026 results (May 11, 2026): Bicara expects FORTIFI-HN01 to be "substantially enrolled by the end of the year" to enable an interim analysis in mid-2027 to support potential accelerated approval; cash, cash equivalents and marketable securities of $539.8 million fund operations "into the first half of 2029"; a Chief Commercial Officer was appointed to "lead the commercial organization in preparation for launch readiness"; the company is "rapidly evolving toward becoming a commercial-stage company".Source
• HiringSenior Director, Brand Lead - US (posted September 25, 2026): the "day-to-day brand owner" who builds the integrated brand plan "across HCP, patient, digital, field, and other customer channels", leads message testing, segmentation and customer journey research, "Day 0 planning", and engagement for "medical oncologists, academic and community oncology practices".Source

Give each guide its own page with a short summary, print-friendly versions and Spanish editions, and give site nurses a printed version.

Shareable resources extend reach to families.

• Outdated guides

  Review yearly.

• Your websitePatients page: a patient quote, downloadable Patient Resource and Caregiver guides, descriptions of FORTIFI-HN01, FORTIFI-FLEX and the Phase 1b study, a Patient Education Center on HNSCC (an estimated 80% of R/M HNSCC cases are HPV-negative) and links to ClinicalTrials.gov and the trial site. The Expanded Access page says Bicara "does not currently offer" expanded access and gives a contact address for healthcare providers.Source